{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T00:08:41Z","timestamp":1789776521485,"version":"4.0.1"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,28]],"date-time":"2024-04-28T00:00:00Z","timestamp":1714262400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","thegreenjournal.com","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Radiotherapy and Oncology"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.radonc.2024.110316","type":"journal-article","created":{"date-parts":[[2024,4,27]],"date-time":"2024-04-27T00:51:44Z","timestamp":1714179104000},"page":"110316","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Neoadjuvant low-dose radiotherapy plus durvalumab and chemotherapy for potentially resectable stage III NSCLC: A phase Ib dose-escalation study"],"prefix":"10.1016","volume":"196","author":[{"given":"Juan","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shun","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuke","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lan","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shao-Hua","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.radonc.2024.110316_b0005","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1016\/j.annonc.2021.08.1994","article-title":"Early and locally advanced non-small-cell lung cancer: an update of the ESMO Clinical Practice Guidelines focusing on diagnosis, staging, systemic and local therapy","volume":"32","author":"Remon","year":"2021","journal-title":"Annals of Oncology : Official Journal of the European Society For Medical Oncology"},{"key":"10.1016\/j.radonc.2024.110316_b0010","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.radonc.2019.03.009","article-title":"Individualized accelerated isotoxic concurrent chemo-radiotherapy for stage III non-small cell lung cancer: 5-Year results of a prospective study","volume":"135","author":"De Ruysscher","year":"2019","journal-title":"Radiotherapy and Oncology : Journal of the European Society For Therapeutic Radiology and Oncology"},{"key":"10.1016\/j.radonc.2024.110316_b0015","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.jtho.2019.10.022","article-title":"Asian thoracic oncology research group expert consensus statement on optimal management of stage III NSCLC","volume":"15","author":"Tan","year":"2020","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.radonc.2024.110316_b0020","unstructured":"Ettinger DS, Wood DE, Aisner DL, Akerley W, Bauman JR, Bharat A, et al. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Non-Small Cell Lung Cancer (Version 3.2023): \u00a9 2021 National Comprehensive Cancer Network, Inc. ; 2023. Available from: Available at https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1450."},{"key":"10.1016\/j.radonc.2024.110316_b0025","doi-asserted-by":"crossref","first-page":"S883","DOI":"10.1016\/j.jtho.2021.08.101","article-title":"OA20.01 long term survival in operable stage iiia nsclc patients treated with neoadjuvant nivolumab plus chemotherapy - nadim study","volume":"16","author":"Provencio","year":"2021","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.radonc.2024.110316_b0030","doi-asserted-by":"crossref","first-page":"1996000","DOI":"10.1080\/2162402X.2021.1996000","article-title":"Phase 2 trial of neoadjuvant toripalimab with chemotherapy for resectable stage III non-small-cell lung cancer","volume":"10","author":"Zhao","year":"2021","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.radonc.2024.110316_b0035","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1056\/NEJMoa2202170","article-title":"Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer","volume":"386","author":"Forde","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.radonc.2024.110316_b0040","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/j.athoracsur.2022.01.039","article-title":"Neoadjuvant sintilimab and chemotherapy for resectable stage IIIA non-small cell lung cancer","volume":"114","author":"Zhang","year":"2022","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.radonc.2024.110316_b0045","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1158\/2326-6066.CIR-14-0191","article-title":"Identification and characterization of MEDI4736, an antagonistic anti-PD-L1 monoclonal antibody","volume":"3","author":"Stewart","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.radonc.2024.110316_b0050","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1016\/j.jtho.2022.07.1148","article-title":"Durvalumab after sequential chemoradiotherapy in stage III, unresectable NSCLC: The phase 2 PACIFIC-6 trial","volume":"17","author":"Garassino","year":"2022","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.radonc.2024.110316_b0055","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S1470-2045(18)30144-X","article-title":"Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study","volume":"19","author":"Garassino","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2024.110316_b0060","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1093\/pcmedi\/pbz004","article-title":"Synergistic effect of immunotherapy and radiotherapy in non-small cell lung cancer: current clinical trials and prospective challenges","volume":"2","author":"Yang","year":"2019","journal-title":"Precision Clinical Medicine"},{"key":"10.1016\/j.radonc.2024.110316_b0065","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.critrevonc.2017.01.017","article-title":"The synergistic effect of radiotherapy and immunotherapy: A promising but not simple partnership","volume":"111","author":"Chajon","year":"2017","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.radonc.2024.110316_b0070","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1038\/s41591-018-0232-2","article-title":"Radiotherapy induces responses of lung cancer to CTLA-4 blockade","volume":"24","author":"Formenti","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.radonc.2024.110316_b0075","doi-asserted-by":"crossref","first-page":"15618","DOI":"10.1038\/ncomms15618","article-title":"DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity","volume":"8","author":"Vanpouille-Box","year":"2017","journal-title":"Nat Commun"},{"key":"10.1016\/j.radonc.2024.110316_b0080","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.trecan.2016.05.002","article-title":"Radiotherapy: Changing the game in immunotherapy","volume":"2","author":"Demaria","year":"2016","journal-title":"Trends In Cancer"},{"key":"10.1016\/j.radonc.2024.110316_b0085","doi-asserted-by":"crossref","first-page":"5792","DOI":"10.1158\/1078-0432.CCR-17-3620","article-title":"The integration of radiotherapy with immunotherapy for the treatment of non-small cell lung cancer","volume":"24","author":"Ko","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.radonc.2024.110316_b0090","unstructured":"Hodge JW, Guha C, Neefjes J, Gulley JL. Synergizing radiation therapy and immunotherapy for curing incurable cancers. Opportunities and challenges. Oncology (Williston Park, NY) 2008;22."},{"key":"10.1016\/j.radonc.2024.110316_b0095","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1097\/JTO.0000000000000686","article-title":"Clinical trials integrating immunotherapy and radiation for non-small-cell lung cancer","volume":"10","author":"Daly","year":"2015","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.radonc.2024.110316_b0100","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.semradonc.2014.07.005","article-title":"Radiotherapy and immunogenic cell death","volume":"25","author":"Golden","year":"2015","journal-title":"Semin Radiat Oncol"},{"key":"10.1016\/j.radonc.2024.110316_b0105","doi-asserted-by":"crossref","first-page":"8556 -","DOI":"10.1200\/JCO.2023.41.16_suppl.8556","article-title":"Phase Ib study of neoadjuvant concurrent chemoradiation plus durvalumab followed by surgery and adjuvant durvalumab for resectable stage III NSCLC","volume":"41","author":"Lee","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2024.110316_b0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2023.216239","article-title":"Tackling the current dilemma of immunotherapy in extensive-stage small cell lung cancer: A promising strategy of combining with radiotherapy","volume":"565","author":"Kang","year":"2023","journal-title":"Cancer Lett"},{"key":"10.1016\/j.radonc.2024.110316_b0115","unstructured":"Ettinger DS, Wood DE, Aisner DL, Akerley W, Bauman JR, Bharat A, et al. Non-small cell lung cancer, version 2. 2021, NCCN clinical practice guidelines in oncology. Journal of the National Comprehensive Cancer Network : JNCCN 2021."},{"key":"10.1016\/j.radonc.2024.110316_b0120","unstructured":"Chinese Society of Clinical Oncology Guideline Working Committee. Chinese Society of Clinical Oncology (CSCO) non-small cell lung cancer guideline 2021. People\u2019s Medical Publishing House 2021."},{"key":"10.1016\/j.radonc.2024.110316_b0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2019.08.032","article-title":"UVB-Induced tumor heterogeneity diminishes immune response in melanoma","volume":"179","author":"Wolf","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.radonc.2024.110316_b0130","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1001\/jamaoncol.2023.3309","article-title":"Durvalumab plus concurrent radiotherapy for treatment of locally advanced non-small cell lung cancer: The DOLPHIN phase 2 nonrandomized controlled trial","volume":"9","author":"Tachihara","year":"2023","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.radonc.2024.110316_b0135","article-title":"SAKK 16\/18: Immune-modulatory radiotherapy to enhance the effects of neoadjuvant PD-L1 blockade after neoadjuvant chemotherapy in patients with resectable stage III (N2) non-small cell lung cancer (NSCLC)\u2014A multicenter phase II trial","author":"Mauti","year":"2023","journal-title":"World conference on lung Cancer"},{"key":"10.1016\/j.radonc.2024.110316_b0140","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.ijrobp.2020.05.002","article-title":"Effect of low-dose radiation therapy on abscopal responses to hypofractionated radiation therapy and anti-PD1 in mice and patients with non-small cell lung cancer","volume":"108","author":"Yin","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2024.110316_b0145","unstructured":"Hong M, Kim H, Lim S, Lee S, Park S, editors. Interim analysis of neoadjuvant chemoradiotherapy (NCRT) and durvalumab for potentially resectable stage III NSCLC, World Conference on Lung Cancer. (2021)."},{"key":"10.1016\/j.radonc.2024.110316_b0150","doi-asserted-by":"crossref","first-page":"20210187","DOI":"10.1259\/bjr.20210187","article-title":"Low-dose radiation therapy for COVID-19 pneumonia: a pilot study","volume":"94","author":"Sharma","year":"2021","journal-title":"Br J Radiol"},{"key":"10.1016\/j.radonc.2024.110316_b0155","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/j.ijrobp.2014.11.030","article-title":"Lung texture in serial thoracic computed tomography scans: correlation of radiomics-based features with radiation therapy dose and radiation pneumonitis development","volume":"91","author":"Cunliffe","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2024.110316_b0160","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.2217\/fon-2020-1222","article-title":"Immune-related adverse events with PD-1 versus PD-L1 inhibitors: a meta-analysis of 8730 patients from clinical trials","volume":"17","author":"Sonpavde","year":"2021","journal-title":"Future Oncology (London, England)"},{"key":"10.1016\/j.radonc.2024.110316_b0165","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1186\/s12885-019-5701-6","article-title":"Immune-related adverse events associated with programmed cell death protein-1 and programmed cell death ligand 1 inhibitors for non-small cell lung cancer: a PRISMA systematic review and meta-analysis","volume":"19","author":"Sun","year":"2019","journal-title":"BMC Cancer"},{"key":"10.1016\/j.radonc.2024.110316_b0170","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.chest.2017.04.177","article-title":"Incidence of pneumonitis with use of programmed death 1 and programmed death-ligand 1 inhibitors in non-small cell lung cancer: A systematic review and meta-analysis of trials","volume":"152","author":"Khunger","year":"2017","journal-title":"Chest"},{"key":"10.1016\/j.radonc.2024.110316_b0175","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1016\/S1470-2045(20)30140-6","article-title":"Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial","volume":"21","author":"Shu","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2024.110316_b0180","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/S1470-2045(20)30453-8","article-title":"Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial","volume":"21","author":"Provencio","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2024.110316_b0185","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1186\/s12916-022-02696-4","article-title":"Safety and effectiveness of neoadjuvant PD-1 inhibitor (toripalimab) plus chemotherapy in stage II-III NSCLC (LungMate 002): an open-label, single-arm, phase 2 trial","volume":"20","author":"Zhu","year":"2022","journal-title":"BMC Med"},{"key":"10.1016\/j.radonc.2024.110316_b0190","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2304875","article-title":"Perioperative durvalumab for resectable non-small-cell lung cancer","author":"Heymach","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.radonc.2024.110316_b0195","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.ccr.2013.09.014","article-title":"Low-dose irradiation programs macrophage differentiation to an iNOS+\/M1 phenotype that orchestrates effective T cell immunotherapy","volume":"24","author":"Klug","year":"2013","journal-title":"Cancer Cell"},{"key":"10.1016\/j.radonc.2024.110316_b0200","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1002\/mc.22879","article-title":"Low dose radiation primed iNOS + M1macrophages modulate angiogenic programming of tumor derived endothelium","volume":"57","author":"Nadella","year":"2018","journal-title":"Mol Carcinog"},{"key":"10.1016\/j.radonc.2024.110316_b0205","first-page":"5711","article-title":"Low dose irradiation increases adoptive cytotoxic T lymphocyte migration in gastric cancer","volume":"14","author":"Du","year":"2017","journal-title":"Exp Ther Med"},{"key":"10.1016\/j.radonc.2024.110316_b0210","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1001\/jamasurg.2023.4395","article-title":"Circulating tumor DNA dynamics as prognostic markers in locally advanced and metastatic esophageal squamous cell carcinoma","volume":"158","author":"Ng","year":"2023","journal-title":"JAMA Surg"},{"key":"10.1016\/j.radonc.2024.110316_b0215","article-title":"Exploration of biomarkers in potentially resectable stage IIIB NSCLC patients receiving neoadjuvant chemoimmunotherapy","volume":"41","author":"Huang","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2024.110316_b0220","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.lungcan.2017.06.014","article-title":"Prognostic and predictive effects of TP53 co-mutation in patients with EGFR-mutated non-small cell lung cancer (NSCLC)","volume":"111","author":"Labb\u00e9","year":"2017","journal-title":"Lung Cancer (Amsterdam, Netherlands)"},{"key":"10.1016\/j.radonc.2024.110316_b0225","doi-asserted-by":"crossref","first-page":"4647","DOI":"10.1158\/1078-0432.CCR-13-2391","article-title":"Nondisruptive p53 mutations are associated with shorter survival in patients with advanced non-small cell lung cancer","volume":"20","author":"Molina-Vila","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.radonc.2024.110316_b0230","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2023.104564","article-title":"bITH, a blood-based metric of intratumor heterogeneity, is associated with clinical response to immune checkpoint blockade in non-small cell lung cancer","volume":"91","author":"Fan","year":"2023","journal-title":"EBioMedicine"},{"key":"10.1016\/j.radonc.2024.110316_b0235","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1186\/s12916-022-02444-8","article-title":"Increased blood-based intratumor heterogeneity (bITH) is associated with unfavorable outcomes of immune checkpoint inhibitors plus chemotherapy in non-small cell lung cancer","volume":"20","author":"Zhou","year":"2022","journal-title":"BMC Med"},{"key":"10.1016\/j.radonc.2024.110316_b0240","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1016\/j.jtho.2020.05.020","article-title":"Neoadjuvant immunotherapy for NSCLC: Current concepts and future approaches","volume":"15","author":"Uprety","year":"2020","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.radonc.2024.110316_b0245","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1111\/cas.15778","article-title":"Tumor immune microenvironment predicts the pathologic response of neoadjuvant chemoimmunotherapy in non\u2013small-cell lung cancer","volume":"114","author":"Han","year":"2023","journal-title":"Cancer Sci"},{"key":"10.1016\/j.radonc.2024.110316_b0250","doi-asserted-by":"crossref","DOI":"10.3390\/ijms242316691","article-title":"Modulation of CD8+ T cell responses by radiotherapy-current evidence and rationale for combination with immune checkpoint inhibitors","volume":"24","author":"Jeon","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.radonc.2024.110316_b0255","doi-asserted-by":"crossref","first-page":"7549","DOI":"10.1245\/s10434-023-14123-w","article-title":"Neoadjuvant chemoimmunotherapy increases tumor immune lymphocytes infiltration in resectable non-small cell lung cancer","volume":"30","author":"Chen","year":"2023","journal-title":"Ann Surg Oncol"}],"container-title":["Radiotherapy and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016781402400238X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016781402400238X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,8]],"date-time":"2024-11-08T01:12:52Z","timestamp":1731028372000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016781402400238X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":51,"alternative-id":["S016781402400238X"],"URL":"https:\/\/doi.org\/10.1016\/j.radonc.2024.110316","relation":{},"ISSN":["0167-8140"],"issn-type":[{"value":"0167-8140","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neoadjuvant low-dose radiotherapy plus durvalumab and chemotherapy for potentially resectable stage III NSCLC: A phase Ib dose-escalation study","name":"articletitle","label":"Article Title"},{"value":"Radiotherapy and Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.radonc.2024.110316","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"110316"}}